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ABSTRACT
Objectives To investigate the cost effectiveness of cyclo-
oxygenase-2 (COX 2) selective inhibitors and traditional
non-steroidal anti-inflammatory drugs (NSAIDs), and the
addition of proton pump inhibitors to these treatments,
for people with osteoarthritis.
Design An economic evaluation using a Markov model
and data from a systematic review was conducted.
Estimates of cardiovascular and gastrointestinal adverse
events were based on data from three large randomised
controlled trials, and observational data were used for
sensitivity analyses. Efficacy benefits from treatmentwere
estimated from a meta-analysis of trials reporting total
Western Ontario and McMaster Universities (WOMAC)
osteoarthritis index score. Other model inputs were
obtained from the relevant literature. The model was run
for a hypothetical population of people with
osteoarthritis. Subgroup analyses were conducted for
people at high risk of gastrointestinal or cardiovascular
adverse events.
Comparators Licensed COX 2 selective inhibitors
(celecoxib and etoricoxib) and traditional NSAIDs
(diclofenac, ibuprofen, and naproxen) for which suitable
data were available were compared. Paracetamol was
also included, as was the possibility of adding a proton
pump inhibitor (omeprazole) to each treatment.
Main outcomemeasures Themain outcomemeasure was
cost effectiveness, which was based on quality adjusted
life years gained. Quality adjusted life year scores were
calculated from pooled estimates of efficacy and major
adverse events (that is, dyspepsia; symptomatic ulcer;
complicated gastrointestinal perforation, ulcer, or bleed;
myocardial infarction; stroke; and heart failure).
Results Addition of a proton pump inhibitor to both COX 2
selective inhibitors and traditional NSAIDs was highly
cost effective for all patient groups considered
(incremental cost effectiveness ratio less than £1000
(€1175, $1650)). This finding was robust across a wide
range of effectiveness estimates if the cheapest proton
pump inhibitor was used. In our base case analysis,
adding a proton pump inhibitor to a COX 2 selective
inhibitor (used at the lowest licensed dose) was a cost
effective option, even for patients at low risk of
gastrointestinal adverse events (incremental cost
effectiveness ratio approximately £10000). Uncertainties
around relative adverse event rates meant relative cost
effectiveness for individual COX 2 selective inhibitors and
traditional NSAIDs was difficult to determine.
Conclusions Prescribing a proton pump inhibitor for
people with osteoarthritis who are taking a traditional
NSAID or COX 2 selective inhibitor is cost effective. The
cost effectiveness analysis was sensitive to adverse event
data and the specific choice of COX 2 selective inhibitor or
NSAID agent should, therefore, take into account
individual cardiovascular and gastrointestinal risks.
INTRODUCTION
Traditional non-steroidal anti-inflammatory drugs
(NSAIDs) and the newer cyclo-oxygenase-2 (COX 2)
selective inhibitors are commonly prescribed for peo-
ple with osteoarthritis. Approximately half of the peo-
ple with osteoarthritis in the United Kingdom who
require medication are treated with an NSAID or a
COX 2 selective inhibitor.1 COX 2 selective agents
are currently prescribed much less often than tradi-
tionalNSAIDs; in 2007, for example, theCOX2 selec-
tive inhibitors celecoxib and etoricoxib accounted for
approximately 5.8% of total NSAID prescriptions in
England and approximately 20% of the total spend.2
Although traditional NSAIDs and COX 2 selective
inhibitors seem similar in terms of symptom relief in
such patients, traditional NSAIDs are associated with
gastrointestinal side effects. COX 2 selective agents
were developed to reduce the gastrointestinal side
effects of this drug class. In addition, concerns have
been raised over the cardiovascular safety of both
COX 2 selective inhibitors and traditional NSAIDs.3 4
New data indicate that co-prescribing gastroprotective
agentswith both traditionalNSAIDs andCOX2 selec-
tive agents is beneficial.5-7
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The latest National Institute for Health and Clinical
Excellence clinical guidance for the management of
osteoarthritis provides an update to previous recom-
mendations on the use of COX 2 selective
inhibitors.8-11 The previous guidance recommended
that these agents should not be used routinely for
patients with osteoarthritis or rheumatoid arthritis
and should only be used in patients at high risk of
developing serious gastrointestinal adverse events on
traditional NSAIDs. In addition, the guidance stated
that there was no evidence to justify the simultaneous
prescription of gastroprotective agents with COX 2
selective inhibitors. This National Institute for Health
and Clinical Excellence guidance and other published
economic analyses in this area preceded the latest evi-
dence on adverse events and gastroprotection,
however.5 9 12 In addition, drug prices have recently
changed—particularly for proton pump inhibitors—
and the cost effectiveness of gastroprotective agents
could, therefore, also change.13
As part of the development of the latest National
Institute for Health and Clinical Excellence guideline,
we performed an economic evaluation ofCOX2 selec-
tive inhibitors and traditionalNSAIDs, andof the addi-
tion of gastroprotective agents to these treatments.
METHODS
We conducted a cost utility analysis according to the
methods recommended by the National Institute for
Health and Clinical Excellence.14 The primary out-
come measure for the economic analysis was quality
adjusted life years. A healthcare payer perspective
was taken—that of the NHS in England andWales.
Comparators
Despite the growth in the evidence base, data are still
sparse regarding the adverse events associated with
some NSAIDs. Amalgamating data from observa-
tional trials with data from randomised controlled
trials was not feasible because of the differences in
patient groups, drug doses, and adverse event
definitions. To obtain evidence with the least risk
of bias, we based our analysis on the largest rando-
mised controlled trials reporting gastrointestinal and
cardiovascular events with currently licensed
NSAIDs: the celecoxib long-term arthritis safety study
(CLASS),15 16 the therapeutic arthritis research and
gastrointestinal event trial (TARGET),17-19 and the
multinational etoricoxib and diclofenac arthritis long-
term (MEDAL) study.20-22 Two of these trials (CLASS
and the MEDAL study) included a minority of people
with rheumatoid arthritis; however, the National Insti-
tute for Health and Clinical Excellence Osteoarthritis
Guideline Development Group considered that the
relative risks of adverse events would be similar in peo-
ple with osteoarthritis and rheumatoid arthritis
because there is no clear evidence of a relationship
between drug induced adverse event rates and arthritis
type.Table 1 gives anoverviewof the characteristics of
the CLASS, TARGET, and the MEDAL study. These
studies allow comparisons between the currently avail-
able COX 2 selective inhibitors (celecoxib and etori-
coxib) and three traditional NSAIDs (diclofenac,
ibuprofen, and naproxen), which together account for
over 80% of NSAID prescriptions in England.2 “No
treatment,” paracetamol, and the addition of a proton
pump inhibitor (omeprazole) to eachNSAIDwere also
considered. Topical NSAIDs were not included owing
to data limitations.
Model design
The economicmodel is described in detail elsewhere.23
Here, we give an overview of the model design and
parameters. The principal inputs to the model are
shown in tables 2, 3, and 4.
The model estimates the net impact of the treatment
options on patient outcomes and expenditure, taking
account of effects on the incidence of gastrointestinal
and cardiovascular adverse events as well as improve-
ments in the control of osteoarthritis symptoms. It is
made up of a series of health states between which a
theoretical cohort of patients canmove.The ratesof tran-
sition between these states are estimated using clinical
evidence. The health states represent the most frequent
and severe adverse events: dyspepsia; symptomatic
ulcer; complicated gastrointestinal perforation, ulcer,
orbleed;myocardial infarction; stroke; andheart failure.
In addition, a patient can experience no adverse event,
or death. Death rates are based on age specific mortality
rates andexcessmortality associatedwith cardiovascular
and gastrointestinal adverse events.2425
The duration of treatment can be altered between
three months and lifetime. The treatment duration
adopted in the base case version of the model was
three months. The model assumes that treatment
effects do not persist after treatment is terminated
Table 1 | Key characteristics of the largest randomised controlled trials reporting gastrointestinal and cardiovascular events
with currently licensed NSAIDs
The multinational etoricoxib
and diclofenac arthritis
long-term (MEDAL) study
The therapeutic arthritis
research and gastrointestinal
event trial (TARGET)
The celecoxib
long-term arthritis safety
study (CLASS)
Number of participants 34 701 18 244 7968
Mean age (years) 63.2 63.4 60.2
Proportion of men (%) 25.8 23.6 31.2
Proportionofpatientswithosteoarthritis (%) 71.8 100 72.8
Drugs compared Etoricoxib, diclofenac Lumiracoxib, ibuprofen,
naproxen
Celecoxib, diclofenac, ibuprofen
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because there is no clear evidence to the contrary. The
model does, however, include the continuing impact
over the patients’ remaining lifetimes of adverse events
experienced during the treatment period. If a patient
experiences dyspepsiawhen being treatedwith aCOX
2 selective inhibitor or traditionalNSAID, this adverse
event is treated and a proton pump inhibitor is added
for the remaining duration of treatment. For patients
who survive other more serious adverse events, the
COX 2 selective inhibitor or traditional NSAID is
stopped and replacedwithparacetamol. Thesepatients
are subsequently at greater risk of having another ser-
ious gastrointestinal or cardiovascular event, based on
post-event risks estimated from the literature.25 26
Patient populations
Results were estimated for a cohort of patients aged 55,
with baseline risks of 21 and42per 10 000person years
for serious gastrointestinal and cardiovascular events,
respectively.26-29 We also ran the model with an older
cohort of patients (age 65) who had a higher baseline
risk (relative risks 2.96 and1.94 for gastrointestinal and
cardiovascular events, respectively).30 31
Adverse events
Adverse event datawere taken from theCLASS, TAR-
GET, and theMEDAL study, and an indirect compar-
ison was conducted. The doses of traditional NSAIDs
given in these key clinical trials are generally high (but
within licensed levels), whereas doses are far above
licensed levels forCOX2 selective inhibitors. This dis-
parity posed problems for our analysis because
adverse events are considered to be dose related. In
this paper, we present results for the lowest licensed
doses that were considered to be effective for patients
with osteoarthritis. The adverse event rates observed in
the randomised controlled trials were adjusted by
assuming that halving the dose results in a reduction
in adverse events of a quarter.32 This assumption is
very important but is uncertain because of the lack of
data available to inform it; therefore, we incorporated
uncertainty over this assumption in the probabilistic
sensitivity analysis.33
The adverse event rates estimated from the rando-
mised controlled trial data and baseline estimates of
risk for the cohort of patients aged 55 are shown in
table 2. The ranges given in this table were used in
the probabilistic sensitivity analysis.
The effect of adding a proton pump inhibitor to tra-
ditional NSAIDs and COX 2 selective agents was esti-
mated from a meta-analysis and trial, respectively.5 6
The reduction in risk was assumed to be the same for
each traditionalNSAIDandalso for eachCOX2 selec-
tive inhibitor because there is not clear evidence to sug-
gest otherwise (table 2).
Costs
Theanalysis included thecost to theNHSof treating side
effects (table 3) as well as drug costs (table 4). The costs
of treating gastrointestinal adverse events were
Table 3 | Model parameters—costs and utilities for all patients
Adverse effect
Dyspepsia
Symptomatic
ulcer
Gastrointestinal
bleed
Myocardial
infarction Stroke Heart failure
Cost of adverse events (£ per 3 months, 2007-8)
Initial 3 months 40 640 2862 1437 2268 1770
After initial3months - 19 19 134 435 134
Utility weights for adverse events (mean (95% CI))
Initial 3 months 0.73 (0.63 to 0.84) 0.55 (0.47 to 0.65) 0.46 (0.37 to 0.56) 0.37 (0.28 to 0.47) 0.35 (0.25 to 0.45) 0.71 (0.61 to 0.81)
After initial3months 1.00 0.98 0.98 0.88 (0.78 to 0.98) 0.71 (0.61 to 0.80) 1.00
Table 2 | Model parameters—adverse event rates for patients aged 55 at low baseline risk of gastrointestinal and
cardiovascular adverse events
Adverse effect
Dyspepsia Symptomatic ulcer
Gastrointestinal
bleed
Myocardial
infarction Stroke Heart failure
Adverse event rates (mean (95% CI) per 10000 person years at risk)
No treatment 3128 14 7 26 11 5
Paracetamol (3000 mg) 5441 14 7 26 11 5
Diclofenac (100 mg) 9582 (8709 to 10503) 56 (41 to 74) 28.1 (19 to 39) 35 (26 to 44) 26 (18 to 34) 9 (5 to 13)
Naproxen (750 mg) 6481 (6091 to 6883) 112 (66 to 169) 30 (15 to 49) 26 (9 to 53) 32 (12 to 62) 34 (0 to 176)
Ibuprofen (1200 mg) 5441 (4972 to 5933) 80 (27 to 161) 30 (6 to 73) 61 (6 to 174) 24 (4 to 60) 34 (0 to 176)
Etoricoxib (30 mg) 5114 (3991 to 6385) 30 (21 to 40) 23 (14 to 33) 35 (25 to 46) 24 (16 to 34) 14 (7 to 22)
Celecoxib (200 mg) 5320 (4917 to 5741) 38 (11 to 80) 20 (4 to 50) 59 (8 to 162) 10 (2 to 25) 16 (0 to 87)
Relative risk of adverse events with the addition of a proton pump inhibitor (mean (95% CI))
NSAIDs 0.43 (0.24 to 0.76) 0.37 (0.30 to 0.46) 0.46 (0.07 to 2.92) 1.00 1.00 1.00
COX 2 selective inhibitors 0.25 (0.03 to 0.78) 0.25 (0.03 to 0.78) 0.25 (0.03 to 0.78) 1.00 1.00 1.00
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estimated on the basis of relevant Healthcare Resource
Group codes and average length of stay, as given by the
Department of Health reference costs.34 Costs of
outpatient appointments and general practitioner con-
sultations were also included and were based on
national unit costs.35 This costing technique was similar
to that used in a recent economic evaluation of gastro-
protective agents.5 The costs of treating cardiovascular
adverse eventswere estimated in a similar way, drawing
on data from theHealthcare Resource Group and aver-
age length of stay reference cost data, as well as data
used in the recentNational Institute forHealth andClin-
ical Excellence clinical guideline for hypertension.25
Drug costs were obtained from the British National
Formulary.36 A discount rate of 3.5% was used for both
costs and benefits, as recommended by the National
Institute for Health and Clinical Excellence.
Quality of life weights
The Western Ontario and McMaster Universities
(WOMAC) osteoarthritis index is the tool most com-
monly used to assess outcomes in osteoarthritis trials.37
We conducted ameta-analysis of totalWOMAC scores
for each treatment and used the “transfer to utility”map-
ping technique toestimatequalityof life utilityweights to
reflect improvements in symptom control.3839 Our
meta-analysis suggested that there was no significant
difference in efficacy between COX 2 selective inhibi-
tors and traditional NSAIDs, and there was no clear
trend with regard to different doses leading to different
efficacy. We therefore assumed equal utility weights for
NSAIDs and COX 2 selective inhibitors for patients
who do not experience adverse events (table 4).23 Both
COX 2 selective inhibitors and traditional NSAIDs
were superior to paracetamol, however, which was
given a lower utility weight.
Utility weights for adverse events were taken from
the literature.12 25 On the basis of a lack of evidence for
short term (threemonth) utility weights formyocardial
infarction and heart failure, we estimated these two
adverse events in relation to the short term stroke
weight.25 40On the basis of the guideline group’s expert
opinion, we assumed that heart failure events that are
caused by use of NSAIDs or COX 2 selective inhibi-
tors are likely to be short term and relatively unserious,
resulting in a relatively high utility score.41
The utility weights for treatment effects and adverse
events were multiplied by age specific utility scores for
the general United Kingdom population taken from the
Health Survey for England, which implies that the treat-
ment effects and adverse events have an equal propor-
tional effect on people of different ages.42
Sensitivity analyses
Weused long term observational adverse event data in
sensitivity analyses to test our model. The determinis-
tic sensitivity analyses undertaken are listed in table 5.
RESULTS
Figure 1 shows the mean estimated gain in quality
adjusted life years and the costs for the 11 treatment
options administered for three months compared
with no treatment.
The addition of a proton pump inhibitor to any of the
COX 2 selective inhibitors or other NSAIDs increases
the estimated gain in quality adjusted life years at little or
no additional cost (once savings fromnot having to treat
adverse effects are taken into account). Co-prescription
of a proton pump inhibitor costs less than £1000 (€1175,
Table 5 | Deterministic sensitivity analyses undertaken
Sensitivity analysis Change tested Reason
Observational data Use observational data for adverse events rather than randomised
controlled trial data
Stroke risk Alter the stroke risk estimates such that both COX 2 selective drugs
(celecoxib and etoricoxib) have the same risk
High uncertainty in the evidence
Dose of NSAIDs Assume diclofenac dose of 150 mg, rather than 100 mg
Assume naproxen dose of 500 mg or 1000 mg rather than 750 mg
Assume ibuprofen dose of 2400 mg rather than 1200 mg.
Heart failure risk Assume same risk of heart failure for all treatment options High uncertainty in the evidence
Myocardial infarction risk Assume ibuprofen, naproxen, and diclofenac are all associated with the
same risk of myocardial infarction
High uncertainty in the evidence
Hip fracture associated with proton
pump inhibitor usage
Assume increased risk of hip fracture with proton pump inhibitor usage New data51 52
Proton pump inhibitor risk reduction Alter the relative risk reduction estimated to result from addition of a
proton pump inhibitor to an NSAID or a COX 2 selective inhibitor
Dose-adverse event relation
Table 4 | Model parameters—drug costs, treatment effects, and utility gains for all patients
Drug cost
(£per3months,
2007-8)
Meta-analysis results (mean (95% CI))
WOMAC
total score
Utility weight
(no adverse effects)
No treatment - 25.54 0.688
Paracetamol (3000 mg) 10.64 23.08 (21.24 to 24.91) 0.701 (0.691 to 0.709)
Diclofenac (100 mg) 4.35
18.01 (16.79 to 19.22) 0.723 (0.718 to 0.727)
Naproxen (750 mg) 8.58
Ibuprofen (1200 mg) 8.01
Etoricoxib (30 mg) 44.97
Celecoxib (200 mg) 64.65
Omeprazole (20 mg) 6.43 - -
WOMAC=Western Ontario and McMaster Universities osteoarthritis scale.
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$1650) per additional quality adjusted life year gained,
even for patients at low risk of gastrointestinal adverse
events. This finding was very robust to sensitivity analy-
sis, provided that the cheapest proton pump inhibitor
(currently omeprazole) was used. In the United King-
dom, an intervention is usually classed as cost effective
if the incremental cost of an additional quality adjusted
life year is less than £20000.14
An incremental cost effectiveness analysis of the
remaining treatment options is shown in table 6. This
analysis suggests that the most effective option, cele-
coxib 200 mg with a proton pump inhibitor, can be
considered cost effective, with an incremental cost
effectiveness ratio estimate of around £10 000 per qual-
ity adjusted life year gained for both the high risk and
the low risk patient groups. There was a high degree of
uncertainty around this finding, however. The cost
effectiveness acceptability curves in figure 2 show
that the probability of celecoxib 200 mg with a proton
pump inhibitor being the most cost effective treatment
option is only 50% at a cost effectiveness threshold of
£30 000 per quality adjusted life year. When we esti-
mated adverse event rates from observational
data, 28 30 43-45 celecoxib 200 mg plus a proton pump
inhibitor was of borderline cost effectiveness com-
pared with ibuprofen 1200 mg plus a proton pump
inhibitor, with incremental cost effectiveness ratios of
£30 400 and £21 000 per quality adjusted life year
gained for 55 and 65 year old patients, respectively.
In addition, debate on the validity of cardiovascular
event data from CLASS casts doubt over the superior-
ity of celecoxib compared with etoricoxib and other
treatments. According to this study, the estimated
stroke rate for patients on celecoxib 200 mg is unex-
pectedly low, with only 10 events per 10 000 person
years at risk, compared with a rate of 24 events per
10 000 person years at risk for etoricoxib 30 mg esti-
mated from the MEDAL study. If we assume that the
stroke risks estimated from theMEDAL study apply to
both the COX 2 selective agents assessed in this study,
etoricoxib 30 mg plus a proton pump inhibitor
becomes the most cost effective option in our model.
No reliable conclusions can be drawn from our
model about the relative cost effectiveness of the tradi-
tional NSAIDs: differences were very small and highly
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Fig 2 | Cost effectiveness acceptability curves for a cohort of
people at low initial risk of gastrointestinal and
cardiovascular events (equivalent to the average risk for a
55 year old) and a cohort at high risk (equivalent to the risk
for an average 65 year old) treated for three months, baseline
assumptions
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Fig 1 | Expected costs and health outcomes for a cohort of people at low initial risk of
gastrointestinal and cardiovascular events (equivalent to the average risk for a 55 year old)
and a cohort at high risk (equivalent to the risk for an average 65 year old) treated for three
months, baseline assumptions
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sensitive to the adverse event rates (figures 1 and2). For
patients at raised gastrointestinal and cardiovascular
risk (equivalent to the average risk for a 65 year old),
however, none of the traditional NSAIDs studiedwere
cost effective compared with paracetamol, even when
combined with a proton pump inhibitor. This is
because the gain in quality adjusted life years from
improved control of osteoarthritis symptoms provided
by the traditional NSAIDs is outweighed by the loss
from NSAID induced adverse events (figure 1).
DISCUSSION
A clear result from this analysis is it is cost effective to
co-prescribe a proton pump inhibitor when either a
COX 2 selective inhibitor or a traditional NSAID is
given, even for patients at relatively low risk of gastro-
intestinal adverse events. This result is driven by recent
improvements in the evidence base for proton pump
inhibitors and reductions in their price.6 7 In the past it
has not been considered usual to co-prescribe a proton
pump inhibitor with a COX 2 selective inhibitor, thus
this recommendation represents a change in current
practice. Assuming a class effect for proton pump inhi-
bitors, the cheapest of these agents will always be cost
effective. At current prices the relative risk of gastro-
intestinal adverse events could be as high as 0.98
before the addition of a proton pump inhibitor
becomes cost ineffective at a cost effectiveness thresh-
old of £20 000 per additional quality adjusted life year.
Another key finding of this analysis is that the co-
prescription of a proton pump inhibitor with a COX
2 selective inhibitor rather than a traditional NSAID
might be a cost effective treatment option for younger
patients without specific gastrointestinal risk factors.
Previously, the use of a COX 2 selective inhibitor
would have been considered only in patients at high
risk of gastrointestinal adverse events. There is uncer-
tainty over this finding, though, primarily owing to
uncertainties over the adverse event data, some of
which are based on low event numbers.
The relative cost effectiveness of the traditional
NSAIDs depended on the adverse event data used.
The sensitivity analyses showed that there is high
uncertainty over which specific NSAID or COX 2
selective inhibitor is most cost effective—the results
were sensitive to most of the analyses run. It is, there-
fore, difficult to make a firm conclusion. The same is
true for the relative cost effectiveness of the two cur-
rently available COX 2 selective inhibitors. For
patients at increased risk of cardiovascular or gastro-
intestinal events (that is, equivalent to the risk of an
average 65 year old), paracetamol results in fewer
Table 6 | Cost effectiveness on the basis of three months of treatment, base case assumptions*
Cost per 10000 people
treated (£)
QALYs gained per 10000
people treated ICER† (£ per QALY) Comparator
People at low risk of gastrointestinal and cardiovascular adverse events (age 55 with no risk factors)
No treatment 0 0.0 - -
Paracetamol (3000 mg)§ 127 708 10.0 - -
Diclofenac (100 mg) plus
proton pump inhibitor
198 117 28.4 6964 No treatment
Naproxen (750 mg) plus
proton pump inhibitor§
298 657 35.2 - -
Ibuprofen (1200 mg) plus
proton pump inhibitor§
350 864 39.1 - -
Etoricoxib (30 mg) plus
proton pump inhibitor
580 668 72.9 7472 Diclofenac (100 mg) plus
proton pump inhibitor
Celecoxib (200 mg) plus
proton pump inhibitor
790 859 92.5 10 745 Etoricoxib (30 mg) plus
proton pump inhibitor
People at high risk of gastrointestinal and cardiovascular adverse events (age 65 or with risk factors)
No treatment 0 0.0 - -
Paracetamol (3000 mg)§ 127 965 10.9 - -
Diclofenac (100 mg) plus
proton pump inhibitor‡
230 640 −26.0 - -
Naproxen (750 mg) plus
proton pump inhibitor‡
352 079 −32.5 - -
Ibuprofen (1200 mg) plus
proton pump inhibitor‡
441 537 −23.6 - -
Etoricoxib (30 mg) plus
proton pump inhibitor§
600 650 46.3 - -
Celecoxib (200 mg) plus
proton pump inhibitor
841 035 80.4 10 458 No treatment
*Note that the results presented here do not exactly match those presented in Osteoarthritis: National clinical guideline for care and management in
adults, Appendix D. This is owing to minor data input changes and also because the model was re-run with etoricoxib 30 mg plus proton pump
inhibitor included in the base case analysis.
†Incremental cost effectiveness ratio (ICER): additional cost per additional quality adjusted life year (QALY) gained comparing each non-dominated
option with the next most expensive, non-dominated option.
‡Treatment subject to “simple dominance”: another option is less expensive and more effective.
§Treatment subject to “extended dominance”: a combination of two other options is less expensive and more effective.
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adverse events and is more cost effective than any of
the traditional NSAIDs co-prescribed with a proton
pump inhibitor, but is not superior to a COX 2 selec-
tive inhibitor with a proton pump inhibitor. For lower
risk patients, prescribing a traditional NSAID or a
COX 2 selective inhibitor with a proton pump inhibi-
tor is likely to be cost effective compared with para-
cetamol.
The relatively high rates of side effects with all of the
traditional NSAIDs and COX 2 selective agents stu-
died, as well as questions over their long term
efficacy,46-48 suggest that these drugs should only be
prescribed to control symptoms of osteoarthritis as
and when required and should be used at the lowest
effective dose for the shortest possible period of time.
Our results are based on the lowest licensed dose con-
sidered to be effective for osteoarthritis.
Previous studies have determined a wide range of
cost effectiveness estimates for COX2 selective inhibi-
tors compared with NSAIDs for people with osteoar-
thritis—some have indicated that COX 2 selective
inhibitors provide cost savings and health gains,
whereas others found that COX 2 selective inhibitors
increase costs and result in health losses.9 12 49 Our
analysis differs because it is based on the most recent
data and includes a range of gastrointestinal and
cardiovascular adverse events. Despite this, we found
that the difference between individual NSAIDs and
COX 2 selective inhibitors remains uncertain. Unlike
previous analyses, however, we found that the addition
of a proton pump inhibitor to both traditionalNSAIDs
and COX 2 selective inhibitors was likely to be cost
effective on the basis of the latest data and prices.
Our analysis also indicates that for people with
osteoarthritis and a low risk of cardiovascular adverse
events, a COX 2 selective inhibitor in combination
with a proton pump inhibitor might be the most cost
effective treatment option. It should be noted that in
our economic model we assessed three months of con-
tinuous use of treatments. This treatment schedulemight
not reflect real world use of these agents, whichmight be
infrequent and for shorter durations in peoplewith inter-
mittently symptomatic osteoarthritis. Most people with
osteoarthritis are elderly and have multiple comorbid-
ities, especially cardiovascular disease, which will ulti-
mately limit the use of COX 2 selective inhibitors. This
fact might be reflected in current prescribing patterns,
given that prescriptions of COX 2 selective inhibitors
form a low proportion of total NSAID prescriptions.2
Our analysis also shows that traditional NSAIDs are
not likely to bemore cost effective thanCOX2 selective
inhibitors for people with osteoarthritis who are at high
risk of cardiovascular adverse events, thus both tradi-
tional NSAIDs and COX 2 selective inhibitors should
be avoided in such patients.4
The limitations of this evaluation are associated with
the small number of large randomised controlled trials
available for inclusion, which restricted the number of
agents that couldbe compared. Ideally, a large trial that
directly compared the available NSAIDs and COX 2
selective inhibitors with andwithout co-prescription of
a proton pump inhibitor and collected data on a range
of gastrointestinal and cardiovascular adverse events
would be used to populate our model. Unfortunately
such data are not available.
The assumptions that we made regarding the rela-
tion between dose and efficacy also represent a limita-
tion of our analysis. We were unable to identify a
relation between dose and efficacy with the trials that
we used, and thus we assumed that the utility scores
associated with each treatment in the absence of
adverse events were independent of dose. This pre-
sumption might not be realistic; however, we are con-
fident that the adverse events included in the model
are the main drivers behind the results and that our
dose-efficacy assumption does not undermine our
findings.
Additionally, the difficulties associated with amalga-
mating randomised controlled trial data and observa-
tional data meant that in the base case a large amount
of informative observational adverse event data were
not used.
Finally, we were aware of new data suggesting that
long term proton pump inhibitor use may be linked to
hip fractures50 51; thus we tested the impact of this pos-
sibility in a sensitivity analysis.We found that hip frac-
tures were so rare that they made no difference to the
results of the economic analysis.
CONCLUSIONS
Although uncertainty around some of the results is
high, our findings clearly indicate that when prescrib-
ing an NSAID or a COX 2 selective inhibitor for
patients with osteoarthritis, it is cost effective to add a
proton pump inhibitor. Co-prescription of a proton
pump inhibitor with a COX 2 inhibitor is a new mes-
sage for clinicians, but this evaluation illustrates that
the number of adverse events avoided is very good
value for money.
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